Combining anticancer drugs with osteoprotective agents in prostate cancer —A contemporary update
Treatment of metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC) is a multimodal and interdisciplinary process that frequently affects an elderly and frail population. In these patients, changes in bone metabolism can imply a significant impact on all-cause morbidity as well as cancer-related outcomes. Uniquely, these changes can rely on metastatic bone disease itself, but also on treatment-related changes in bone mineral density that are inherent to long-term androgen deprivation therapy (ADT).
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Cristian Mirvald, Giorgio Gandaglia, Alberto Briganti, Roderick van den Bergh, Derya Tilki, Piet Ost, Guillaume Ploussard, Cristian Surcel, On behalf of the EAU-YAU Prostate Cancer Work Tags: Review article Source Type: research